



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Ariel Fletcher  
Ariel Fletcher

11/18/2004  
Date of deposit

Applicant: Yu )  
Serial No.: 09/935,386 ) Group: 1632  
Filed: August 22, 2001 ) Confirmation No.: 1866  
For: IN VIVO ANIMAL MODEL OF ) Examiner: T. N. Ton  
HUMAN LEUKEMIA ) Our Ref.TSRI 753.1

OK to enter  
3.1.05  
TNT

RESPONSE AND AMENDMENT

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This Response and Amendment is being filed in response to the Office Action mailed on September 20, 2004 issued in association with the above-captioned application. Enclosed is a Notice of Appeal and a check in the amount of \$340.00. Please amend the above-identified application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks** begin on page 4 of this paper.

This listing of claims will replace all prior versions, and listings, of claims in the application:

*OK to enter  
3.1.05  
TNT*  
Listing of Claims:

1. (Currently amended) A process for making an *in vivo* model of human leukemia comprising

a) pre-conditioning an immunodeficient mouse by administering to the mouse a sub-lethal dose of irradiation and injecting the mouse with an effective pre-conditioning amount of mononuclear cells derived from human fetal cord blood;

b) maintaining the mouse from step (a) for 5 to 10 days;  
and

c) injecting the mouse from step (b) with an effective engrafting amount of primary human leukemia cells; and

d) allowing the primary human leukemia cells to engraft in the mouse to produce the *in vivo* model of human leukemia.

2. (Canceled)

3. (Previously presented) The process of claim 1 wherein the immunodeficient mouse is a NOD/scid mouse.

4. (Previously presented) The process of claim 1 wherein administering the sub-lethal dose of irradiation is accomplished by irradiating the mouse with 300 to 400 rads of total body gamma radiation.

5. (Previously presented) The process of claim 1 wherein the effective engrafting amount of primary human leukemia cells is from  $10^6$  to  $10^7$  cells.

6. (Original) The process of claim 1 wherein the primary human leukemia cells are T-cell acute lymphoblastic leukemia (T-